Piper Jaffray analyst Joseph Catanzaro notes that Stemline was granted approval for a new technology add-on payment for Elzonris, which allows for additional reimbursement for Medicare patients beyond the DRG-based payment. While notable, within the CMS decision is further detail around Elzonris dosing that could have "significant positive" implications to his model assumptions. Mainly, the analyst may be under-modeling the number of vials per dose and pricing per newly diagnosed patient may be 90% more than he was modeling. Catanzaro reiterates an Overweight rating and $25 price target on the shares.